iBio (IBIO) Receivables - Net (2011 - 2025)

iBio (IBIO) posted quarterly Receivables - Net of $65000.0 for Q3 2025, down 7.14% quarter-over-quarter from $70000.0 in Q1 2023.

iBio (IBIO) Receivables - Net (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Receivables - Net for 14 consecutive years, with $65000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Receivables - Net changed N/A year-over-year to $65000.0; the TTM figure through Sep 2025 stood at $65000.0 (changed N/A YoY), while the FY2022 annual figure was $1.0 million, up 134.74% from the prior year.
Receivables - Net eased to $65000.0 in Q3 2025 per IBIO's latest filing, from $70000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $1.1 million in Q3 2022 and bottomed at $65000.0 in Q3 2025.
Historically, Receivables - Net has averaged $529500.0 across 4 years, with a median of $406500.0 in 2021.
Annual changes were most pronounced in 2022 — Receivables - Net soared 773.87% — and 2023, when it slumped 93.03%.
iBio's Receivables - Net stood at $111000.0 in 2021, then jumped by 773.87% to $970000.0 in 2022, then plunged by 92.78% to $70000.0 in 2023, then retreated by 7.14% to $65000.0 in 2025.
Business Quant data shows IBIO's Receivables - Net at $65000.0 in Q3 2025, $70000.0 in Q1 2023, and $970000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.59 Bn	131.73 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.21 Bn	78.22 Bn	3.93 Bn
3	Argenx Se	65.65 Bn	60.47 Bn	1.37 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn
7	BioNTech SE	27.90 Bn	9.51 Bn	668.28 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-
10	iBio	172.22 Mn	172.22 Mn	-

Download Data